Glomerular Endothelial Mitochondrial Dysfunction Is Essential and Characteristic of Diabetic Kidney Disease Susceptibility
暂无分享,去创建一个
V. D’Agati | Liping Yu | Yezhou Sun | B. Haraldsson | E. Böttinger | G. Casalena | Weijia Zhang | S. Shi | D. Schlondorff | K. Ebefors | Ilse S. Daehn | Haiying Qi | Weijia Zhang
[1] P. Groop,et al. Incidence of end-stage renal disease in patients with type 1 diabetes. , 2005, Journal of the American Medical Association (JAMA).
[2] C. Dessy,et al. Hyaluronidase 1 Deficiency Preserves Endothelial Function and Glycocalyx Integrity in Early Streptozotocin-Induced Diabetes , 2016, Diabetes.
[3] T. Rabelink,et al. Endothelin-1 Induces Proteinuria by Heparanase-Mediated Disruption of the Glomerular Glycocalyx. , 2016, Journal of the American Society of Nephrology : JASN.
[4] A. Koster,et al. Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy , 2016, Diabetes.
[5] E. Bottinger,et al. TGFβ-Induced Actin Cytoskeleton Rearrangement in Podocytes Is Associated with Compensatory Adaptation of Mitochondrial Energy Metabolism , 2015, Nephron.
[6] J. He,et al. Reduced Krüppel-like Factor 2 expression may aggravate the endothelial injury of diabetic nephropathy , 2014, Kidney international.
[7] E. Araki,et al. Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy , 2014, Journal of diabetes investigation.
[8] H. Parving,et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.
[9] D. Webb,et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. , 2014, Journal of the American Society of Nephrology : JASN.
[10] V. D’Agati,et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. , 2014, The Journal of clinical investigation.
[11] J. McMurray,et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. , 2013, The New England journal of medicine.
[12] B. Viollet,et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. , 2013, The Journal of clinical investigation.
[13] H. Szeto,et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. , 2013, Journal of the American Society of Nephrology : JASN.
[14] M. Murphy,et al. Mitochondrially targeted compounds and their impact on cellular bioenergetics☆ , 2013, Redox biology.
[15] John F. Bertram,et al. Glomerular Endothelial Cell Injury and Damage Precedes That of Podocytes in Adriamycin-Induced Nephropathy , 2013, PloS one.
[16] Yuichiro Yamada,et al. SOD1, but not SOD3, deficiency accelerates diabetic renal injury in C57BL/6-Ins2(Akita) diabetic mice. , 2012, Metabolism: clinical and experimental.
[17] K. Connelly,et al. eNOS deficiency predisposes podocytes to injury in diabetes. , 2012, Journal of the American Society of Nephrology : JASN.
[18] B. Coll,et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). , 2012, Life sciences.
[19] R. Nelson,et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy , 2012, Kidney international.
[20] B. Haraldsson,et al. The glomerular endothelium: new insights on function and structure , 2012, Current opinion in nephrology and hypertension.
[21] P. Karran,et al. 6‐Thioguanine damages mitochondrial DNA and causes mitochondrial dysfunction in human cells , 2011, FEBS letters.
[22] Y. Uchijima,et al. Identification and developmental analysis of endothelin receptor type-A expressing cells in the mouse kidney. , 2011, Gene expression patterns : GEP.
[23] A. Fogo,et al. The glomerulus--a view from the inside--the endothelial cell. , 2010, The international journal of biochemistry & cell biology.
[24] S. Chakrabarti,et al. Glucose-induced endothelin-1 expression is regulated by ERK5 in the endothelial cells and retina of diabetic rats. , 2010, Canadian journal of physiology and pharmacology.
[25] V. Darley-Usmar,et al. Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species. , 2010, Free radical biology & medicine.
[26] C. Alpers,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[27] M. Ohno,et al. Construction and characterization of a cell line deficient in repair of mitochondrial, but not nuclear, oxidative DNA damage. , 2009, Methods in molecular biology.
[28] M. Ohno,et al. Quantitative analysis of oxidized guanine, 8-oxoguanine, in mitochondrial DNA by immunofluorescence method. , 2009, Methods in molecular biology.
[29] Matthias Merkenschlager,et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. , 2008, Journal of the American Society of Nephrology : JASN.
[30] M. Cooper,et al. Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes , 2008, Diabetes.
[31] H. Parving,et al. Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years , 2008, Diabetes Care.
[32] J. Trnka,et al. A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. , 2008, Free radical biology & medicine.
[33] Jenny Nyström,et al. Properties of the Glomerular Barrier and Mechanisms of Proteinuria , 2022 .
[34] S. Satchell,et al. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? , 2008, Diabetologia.
[35] M. Caramori,et al. Podocyte Detachment and Reduced Glomerular Capillary Endothelial Fenestration in Human Type 1 Diabetic Nephropathy , 2007, Diabetes.
[36] B. Ballermann. Contribution of the Endothelium to the Glomerular Permselectivity Barrier in Health and Disease , 2007, Nephron Physiology.
[37] H. Parving,et al. Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria , 2006, Diabetes.
[38] R. Harris,et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. , 2006, Journal of the American Society of Nephrology : JASN.
[39] C. Palmeira,et al. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. , 2006, Toxicology and applied pharmacology.
[40] T. Kern,et al. Association between endothelin-1 and collagen deposition in db/db diabetic mouse kidneys. , 2006, Biochemical and biophysical research communications.
[41] T. Meyer,et al. Impact of genetic background on nephropathy in diabetic mice. , 2006, American journal of physiology. Renal physiology.
[42] M. Schiffer,et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. , 2006, Diabetes.
[43] Jianping Jin,et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. , 2005, Diabetes.
[44] E. Ritz,et al. Nephron number and renal risk in hypertension and diabetes. , 2005, Journal of the American Society of Nephrology : JASN.
[45] Haifeng Guo,et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[46] K. Takahashi,et al. Elevated plasma endothelin in patients with diabetes mellitus , 1990, Diabetologia.
[47] K. Sharma,et al. Genomic strategies for diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.
[48] Li-jun Ma,et al. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. , 2003, Kidney international.
[49] S. Yusuf,et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. , 2002, Diabetes care.
[50] M. Brownlee. Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.
[51] T. Lüscher,et al. Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.
[52] J. Rosenblatt,et al. Analysis of gene-specific DNA damage and repair using quantitative polymerase chain reaction. , 2000, Methods.
[53] Y. Kaneda,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.
[54] R. G. Nelson,et al. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria , 1999, Diabetologia.
[55] Y. Hinokio,et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. , 1999, Diabetes research and clinical practice.
[56] H. Schägger,et al. Altered gene expression and functions of mitochondria in human nephrotic syndrome , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[57] H. Rüdiger,et al. Assay for the determination of urinary 8-hydroxy-2'-deoxyguanosine by high-performance liquid chromatography with electrochemical detection. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[58] Y. Hirata,et al. A novel ETA antagonist (BQ‐123) inhibits endothelin‐1‐induced phosphoinositide breakdown and DNA synthesis in rat vascular smooth muscle cells , 1992, FEBS letters.
[59] L. Oberley. Free radicals and diabetes. , 1988, Free radical biology & medicine.